2020
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinghoff IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn JC, Tsang J, Verhaak RGW, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology 2020, 22: 1073-1113. PMID: 32328653, PMCID: PMC7594557, DOI: 10.1093/neuonc/noaa106.Peer-Reviewed Original ResearchConceptsNeuro-oncologyConsensus reviewCurrent managementMalignant primary brain tumorIsocitrate dehydrogenase-wildtype glioblastomaPrimary brain tumorsNovel therapiesViral therapyBrain tumorsImportant causeMolecular pathogenesisMolecular therapyEuropean AssociationTherapyEuropean SocietyCommon formGlioblastomaWildtype glioblastomaTumorsFuture directionsImportant advancesImmunotherapyMorbidityPatientsDNA damage response
2019
Targeting DNA repair in gliomas.
Beckta JM, Bindra RS, Chalmers AJ. Targeting DNA repair in gliomas. Current Opinion In Neurology 2019, 32: 878-885. PMID: 31592790, DOI: 10.1097/wco.0000000000000760.Peer-Reviewed Original ResearchConceptsLocal controlPoor local controlBlood-brain barrierTreatment of gliomaOverall survivalSystemic treatmentClinical outcomesDismal prognosisAggressive entityPreclinical dataPatient outcomesRadiation therapyGliomasOutcomesDNA repair targetsTreatmentRepair mechanismsRepair targetsNovel chemoCurrent understandingPatientsPrognosisDNA damage responseMalignancy
2018
Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes
Cecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, Goldberg SB. Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes. The Lancet Oncology 2018, 19: 23-24. PMID: 29304353, DOI: 10.1016/s1470-2045(17)30916-6.Peer-Reviewed Case Reports and Technical Notes
2017
Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas
Yeboa DN, Rutter CE, Park HS, Lester-Coll NH, Corso CD, Mancini BR, Bindra RS, Contessa J, Yu JB. Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas. Radiotherapy And Oncology 2017, 125: 258-265. PMID: 29054377, DOI: 10.1016/j.radonc.2017.09.027.Peer-Reviewed Original ResearchConceptsUse of CCRTConcurrent chemoradiotherapyPatterns of careAnaplastic gliomasOverall survivalCox proportional hazards regression modelingProportional hazards regression modelingMultivariable logistic regression analysisConcurrent CRTNational Cancer DatabaseKaplan-Meier analysisLog-rank testLogistic regression analysisGrade III gliomasAdjusted hazardAdult patientsImproved survivalCancer DatabaseDesign cohortRadiotherapyPropensity scorePatientsGliomasChemoradiotherapyRegression modeling
2016
Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery.
Rutter CE, Johung KL, Yao X, Lu AY, Jilaveanu LB, Yu JB, Contessa JN, Kluger HM, Chiang VLS, Bindra RS. Demonstration of differential radiosensitivity based upon mutation profile in metastatic melanoma treated with stereotactic radiosurgery. Journal Of Radiosurgery And SBRT 2016, 4: 97-106. PMID: 29296434, PMCID: PMC5658871.Peer-Reviewed Original ResearchWild-type patientsC-kit mutationsLocal recurrenceMetastatic melanomaBrain metastasesType patientsN-RASCox proportional hazards modelMelanoma brain metastasesImproved local controlLocal recurrence rateProportional hazards modelN-RAS mutationsB-RafDifferential radiosensitivityDistant failureRecurrence rateImportant treatmentStereotactic radiosurgeryHazards modelPatientsLocal controlMultivariate analysisStandardized imagingRecurrence
2015
Adjuvant hypofractionated partial-brain radiation therapy for pediatric Ewing sarcoma brain metastases: case report.
van Dams R, Park HS, Alomari AK, Ricciardi AS, Rao H, McNamara J, DiLuna ML, Bindra RS. Adjuvant hypofractionated partial-brain radiation therapy for pediatric Ewing sarcoma brain metastases: case report. Journal Of Neurosurgery Pediatrics 2015, 17: 434-8. PMID: 26636250, DOI: 10.3171/2015.8.peds15313.Peer-Reviewed Original ResearchConceptsPartial brain radiation therapyRadiation therapyCase reportSarcoma brain metastasesEvidence of diseaseGross tumor resectionGross total resectionBrain metastasesInflammatory changesIntracranial metastasesSarcoma metastasisTumor resectionMetastasisTherapyResectionPatientsLimited marginReasonable approachReportDexamethasoneDiseaseGyBrainMonths
2014
Delayed Cerebral Vasculopathy Following Cranial Radiation Therapy for Pediatric Tumors
Wang C, Roberts KB, Bindra RS, Chiang VL, Yu JB. Delayed Cerebral Vasculopathy Following Cranial Radiation Therapy for Pediatric Tumors. Pediatric Neurology 2014, 50: 549-556. PMID: 24739378, DOI: 10.1016/j.pediatrneurol.2013.09.018.Peer-Reviewed Original ResearchConceptsMedian interval periodIntracerebral hemorrhageMoyamoya syndromeInterval periodCranial radiation therapyRadiation doseIntracerebral hemorrhage casesMoyamoya casesCerebral vasculopathyCerebrovascular injuryMedian agePatient agePediatric patientsDoses of radiationDisease presentationPediatric tumorsRadiation therapyHemorrhage casesHemorrhagePatientsCerebrovasculopathySignificant associationMoyamoyaSyndromeTime of radiation